Target N. V. Biotech, 10% Owner at Esperion Therapeutics, Inc. (ESPR), bought 80,000 shares at $41.29 ($3.3M) on 2019-01-04, disclosed to the SEC on 2019-01-07.
Open-market purchase of $3.3M ESPR by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Negative factors outweigh the positive ones.
| Filing → |
| MGNX | BUY | 2023-01-23 | $795K | — | Filing → |
| MGNX | BUY | 2022-11-25 | $1.8M | — | Filing → |
| MTEM | BUY | 2022-05-18 | $236K | — | Filing → |